CEO Saqib Islam was paid $16,153,317 in fiscal year 2024, ↓ down 12.0% from fiscal year 2023, the 86th percentile of its disclosed peer group (SEC filing 0001104659-25-032187 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$16,153,317 ↓ Saqib Islam total, FY2024 | 86th CEO pay percentile vs peers | 36:1 CEO-to-median pay ratio | 93.73% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Saqib Islam | $760,000 | $0 | $7,899,760 | $6,689,100 | $798,000 | $0 | $6,457 | $16,153,317 |
| Chief Executive Officer | ||||||||
| Badreddin Edris | 620,000 | 0 | 1,624,781 | 3,210,768 | 484,220 | 0 | 1,600 | 5,941,369 |
| Chief Operating Officer | ||||||||
| James Cassidy | 525,000 | 0 | 1,083,187 | 2,140,512 | 330,750 | 0 | 8,625 | 4,088,074 |
| Chief Medical Officer | ||||||||
| Bhavesh Ashar | 525,000 | 0 | 1,015,488 | 2,006,730 | 330,750 | 0 | 9,342 | 3,887,310 |
| Chief Commercial Officer | ||||||||
| Francis Perier | 510,000 | 0 | 812,390 | 1,605,384 | 298,350 | 0 | 0 | 3,226,124 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Saqib Islam | $16,153,317 | $18,351,489 | $15,295,291 | ↓ −2,198,172 |
| Badreddin Edris | 5,941,369 | 6,638,992 | 5,676,558 | ↓ −697,623 |
| James Cassidy | 4,088,074 | 4,309,486 | 2,828,013 | ↓ −221,412 |
| Bhavesh Ashar | 3,887,310 | 2,791,455 | 4,943,009 | ↑ +1,095,855 |
| Francis Perier | 3,226,124 | 3,739,600 | 4,078,690 | ↓ −513,476 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read SpringWorks Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper SWTX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name SWTX as a peer is temporarily unavailable — recheck shortly.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2024 total |
|---|---|---|
| Bhavesh Ashar | CCO | $3,887,310 |
| Badreddin Edris | COO | $5,941,369 |
| James Cassidy | Chief Medical Officer | $4,088,074 |
| Saqib Islam | CEO | $16,153,317 |
| Francis Perier | CFO | $3,226,124 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2024 total |
|---|---|---|
| Alan Fuhrman | Independent Director | $625,239 |
| Carlos Albán | Independent Director | $612,739 |
| Daniel S. Lynch | Independent Director | $650,239 |
| Freda Lewis-Hall | Independent Director | $620,239 |
| Julie Hambleton | Independent Director | $625,239 |
| Martin Mackay | Independent Director | $1,129,205 |
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Carlos Alban | Director | 2025-05-14 | A | 10,060 | $0 | $0 | Common | Form 4 ↗ |
| Freda Lewis-Hall | Director | 2025-05-14 | A | 10,060 | 0 | 0 | Common | Form 4 ↗ |
| Martin Mackay | Director | 2025-05-14 | A | 10,060 | 0 | 0 | Common | Form 4 ↗ |
| Alan Fuhrman | Director | 2025-05-14 | A | 10,060 | 0 | 0 | Common | Form 4 ↗ |
| Julie Hambleton | Director | 2025-05-14 | A | 10,060 | 0 | 0 | Common | Form 4 ↗ |
| Daniel S. Lynch | Director | 2025-05-14 | A | 10,060 | 0 | 0 | Common | Form 4 ↗ |
| Francis Perier | Chief Financial Officer | 2025-07-01 | D | 14,724 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel S. Lynch | Director | 2025-07-01 | D | 15,318 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel S. Lynch | Director | 2025-07-01 | D | 7,464 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel S. Lynch | Director | 2025-07-01 | D | 13,774 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel S. Lynch | Director | 2025-07-01 | D | 6,447 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Freda Lewis-Hall | Director | 2025-07-01 | D | 24,727 | — | — | Common | Form 4 ↗ |
| Daniel S. Lynch | Director | 2025-07-01 | D | 12,216 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel S. Lynch | Director | 2025-07-01 | D | 93,004 | — | — | Common | Form 4 ↗ |
| Badreddin Edris | Chief Operating Officer | 2025-07-01 | D | 78,960 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Badreddin Edris | Chief Operating Officer | 2025-07-01 | D | 120,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Badreddin Edris | Chief Operating Officer | 2025-07-01 | D | 149,470 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Herschel S. Weinstein | General Counsel & Secretary | 2025-07-01 | D | 35,431 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Herschel S. Weinstein | General Counsel & Secretary | 2025-07-01 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Herschel S. Weinstein | General Counsel & Secretary | 2025-07-01 | D | 125,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saqib Islam | Director | 2025-07-01 | D | 109,329 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Pichl | Chief People Officer | 2025-07-01 | D | 65,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Pichl | Chief People Officer | 2025-07-01 | D | 64,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Pichl | Chief People Officer | 2025-07-01 | D | 16,023 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Pichl | Chief People Officer | 2025-07-01 | D | 50,762 | — | — | Common | Form 4 ↗ |
| Michael Nofi | Chief Accounting Officer | 2025-07-01 | D | 20,246 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Nofi | Chief Accounting Officer | 2025-07-01 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Nofi | Chief Accounting Officer | 2025-07-01 | D | 78,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Nofi | Chief Accounting Officer | 2025-07-01 | D | 8,661 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Nofi | Chief Accounting Officer | 2025-07-01 | D | 30,623 | — | — | Common | Form 4 ↗ |
| Carlos Alban | Director | 2025-07-01 | D | 12,216 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Carlos Alban | Director | 2025-07-01 | D | 13,774 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Cassidy | Chief Medical Officer | 2025-07-01 | D | 80,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Cassidy | Chief Medical Officer | 2025-07-01 | D | 135,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bhavesh Ashar | Chief Commercial Officer | 2025-07-01 | D | 70,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bhavesh Ashar | Chief Commercial Officer | 2025-07-01 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bhavesh Ashar | Chief Commercial Officer | 2025-07-01 | D | 62,053 | — | — | Common | Form 4 ↗ |
| Tai-An Lin | Chief Scientific Officer | 2025-07-01 | D | 20,246 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tai-An Lin | Chief Scientific Officer | 2025-07-01 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tai-An Lin | Chief Scientific Officer | 2025-07-01 | D | 8,661 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alan Fuhrman | Director | 2025-07-01 | D | 12,216 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alan Fuhrman | Director | 2025-07-01 | D | 15,318 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alan Fuhrman | Director | 2025-07-01 | D | 29,983 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Freda Lewis-Hall | Director | 2025-07-01 | D | 15,318 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Badreddin Edris | Chief Operating Officer | 2025-07-01 | D | 169,712 | — | — | Common | Form 4 ↗ |
| Herschel S. Weinstein | General Counsel & Secretary | 2025-07-01 | D | 106,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saqib Islam | Director | 2025-07-01 | D | 954,869 | — | — | Common | Form 4 ↗ |
| Alan Fuhrman | Director | 2025-07-01 | D | 7,464 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Freda Lewis-Hall | Director | 2025-07-01 | D | 13,774 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Herschel S. Weinstein | General Counsel & Secretary | 2025-07-01 | D | 15,157 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Herschel S. Weinstein | General Counsel & Secretary | 2025-07-01 | D | 55,239 | — | — | Common | Form 4 ↗ |
| Saqib Islam | Director | 2025-07-01 | D | 325,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saqib Islam | Director | 2025-07-01 | D | 22,760 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saqib Islam | Director | 2025-07-01 | D | 579,749 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Francis Perier | Chief Financial Officer | 2025-07-01 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Francis Perier | Chief Financial Officer | 2025-07-01 | D | 125,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Francis Perier | Chief Financial Officer | 2025-07-01 | D | 60,889 | — | — | Common | Form 4 ↗ |
| Martin Mackay | Director | 2025-07-01 | D | 29,445 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Cassidy | Chief Medical Officer | 2025-07-01 | D | 50,615 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bhavesh Ashar | Chief Commercial Officer | 2025-07-01 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bhavesh Ashar | Chief Commercial Officer | 2025-07-01 | D | 21,654 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tai-An Lin | Chief Scientific Officer | 2025-07-01 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Tai-An Lin | Chief Scientific Officer | 2025-07-01 | D | 33,039 | — | — | Common | Form 4 ↗ |
| Francis Perier | Chief Financial Officer | 2025-07-01 | D | 368,923 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Badreddin Edris | Chief Operating Officer | 2025-07-01 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Badreddin Edris | Chief Operating Officer | 2025-07-01 | D | 3,868 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Carlos Alban | Director | 2025-07-01 | D | 28,861 | — | — | Common | Form 4 ↗ |
| Freda Lewis-Hall | Director | 2025-07-01 | D | 7,464 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Freda Lewis-Hall | Director | 2025-07-01 | D | 12,216 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Freda Lewis-Hall | Director | 2025-07-01 | D | 29,983 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martin Mackay | Director | 2025-07-01 | D | 20,023 | — | — | Common | Form 4 ↗ |
| Alan Fuhrman | Director | 2025-07-01 | D | 13,774 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alan Fuhrman | Director | 2025-07-01 | D | 24,727 | — | — | Common | Form 4 ↗ |
| Francis Perier | Chief Financial Officer | 2025-07-01 | D | 34,419 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Francis Perier | Chief Financial Officer | 2025-07-01 | D | 75,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Cassidy | Chief Medical Officer | 2025-07-01 | D | 81,731 | — | — | Common | Form 4 ↗ |
| James Cassidy | Chief Medical Officer | 2025-07-01 | D | 21,654 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bhavesh Ashar | Chief Commercial Officer | 2025-07-01 | D | 50,615 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Julie Hambleton | Director | 2025-07-01 | D | 15,318 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Julie Hambleton | Director | 2025-07-01 | D | 14,668 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel S. Lynch | Director | 2025-07-01 | D | 232,376 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Julie Hambleton | Director | 2025-07-01 | D | 12,216 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Julie Hambleton | Director | 2025-07-01 | D | 14,155 | — | — | Common | Form 4 ↗ |
| Saqib Islam | Director | 2025-07-01 | D | 260,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saqib Islam | Director | 2025-07-01 | D | 769,804 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel S. Lynch | Director | 2025-07-01 | D | 29,983 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saqib Islam | Director | 2025-07-01 | D | 176,411 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Badreddin Edris | Chief Operating Officer | 2025-07-01 | D | 240,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Badreddin Edris | Chief Operating Officer | 2025-07-01 | D | 33,778 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saqib Islam | Director | 2025-07-01 | D | 250,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Carlos Alban | Director | 2025-07-01 | D | 30,160 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Nofi | Chief Accounting Officer | 2025-07-01 | D | 65,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Pichl | Chief People Officer | 2025-07-01 | D | 37,455 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Pichl | Chief People Officer | 2025-07-01 | D | 72,680 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| James Cassidy | RSU | 2024-01-04 | — | — | 28,208 | — | $1,083,187 |
| Saqib Islam | RSU | 2024-01-04 | — | — | 88,000 | — | 3,379,200 |
| Bhavesh Ashar M.B.A. | RSU | 2024-01-04 | — | — | 26,445 | — | 1,015,488 |
| Saqib Islam | PSU | 2024-01-04 | — | 88,000 | — | 132,000 | 4,520,560 |
| Francis I. Perier Jr. M.B.A. | RSU | 2024-01-04 | — | — | 21,156 | — | 812,390 |
| Badreddin Edris | RSU | 2024-01-04 | — | — | 42,312 | — | 1,624,781 |
| Bhavesh Ashar | RSU | 2024-01-04 | — | — | 26,445 | — | 1,015,488 |
| Francis Perier | RSU | 2024-01-04 | — | — | 21,156 | — | 812,390 |
| Bhavesh Ashar M.B.A. | OPTION | 2024-01-04 | — | — | 75,000 | — | 2,006,730 |
| James Cassidy | OPTION | 2024-01-04 | — | — | 80,000 | — | 2,140,512 |
| Badreddin Edris | OPTION | 2024-01-04 | — | — | 120,000 | — | 3,210,768 |
| Francis I. Perier Jr. M.B.A. | OPTION | 2024-01-04 | — | — | 60,000 | — | 1,605,384 |
| Saqib Islam | OPTION | 2024-01-04 | — | — | 250,000 | — | 6,689,100 |
| Bhavesh Ashar | OPTION | 2024-01-04 | — | — | 75,000 | — | 2,006,730 |
| Francis Perier | OPTION | 2024-01-04 | — | — | 60,000 | — | 1,605,384 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| James Cassidy | $1,083,187 | $0 | $2,140,512 | 0.0% |
| Saqib Islam | 3,379,200 | 4,520,560 | 6,689,100 | 31.0% |
| Bhavesh Ashar M.B.A. | 1,015,488 | 0 | 2,006,730 | 0.0% |
| Francis I. Perier Jr. M.B.A. | 812,390 | 0 | 1,605,384 | 0.0% |
| Badreddin Edris | 1,624,781 | 0 | 3,210,768 | 0.0% |
| Bhavesh Ashar | 1,015,488 | 0 | 2,006,730 | 0.0% |
| Francis Perier | 812,390 | 0 | 1,605,384 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Saqib Islam | PSU | 284,362 | — | $10,273,999 |
| Saqib Islam | RSU | 88,000 | — | 3,179,440 |
| Saqib Islam | PSU | 88,000 | — | 3,179,440 |
| Saqib Islam | RSU | 56,398 | — | 2,037,660 |
| Badreddin Edris | RSU | 42,312 | — | 1,528,733 |
| James Cassidy | RSU | 28,208 | — | 1,019,155 |
| Saqib Islam | RSU | 26,646 | — | 962,720 |
| Bhavesh Ashar | RSU | 26,445 | — | 955,458 |
| Badreddin Edris | RSU | 22,776 | — | 822,897 |
| Francis Perier | RSU | 21,156 | — | 764,366 |
| Bhavesh Ashar | RSU | 15,185 | — | 548,634 |
| James Cassidy | RSU | 15,185 | — | 548,634 |
| Badreddin Edris | Option | 2,167 | 70.68 | — |
| Francis Perier | RSU | 13,015 | — | 470,232 |
| Badreddin Edris | RSU | 8,883 | — | 320,943 |
| Francis Perier | RSU | 6,396 | — | 231,087 |
| Bhavesh Ashar | RSU | 4,442 | — | 160,489 |
| James Cassidy | RSU | 3,833 | — | 138,486 |
| Saqib Islam | Option | 6,250 | 70.68 | — |
| Saqib Islam | Option | 66,154 | 59.46 | — |
| Saqib Islam | Option | 135,417 | 27.64 | — |
| Saqib Islam | Option | 192,709 | 38.4 | — |
| Francis Perier | Option | 1,667 | 70.68 | — |
| Francis Perier | Option | 15,877 | 59.46 | — |
| James Cassidy | Option | 8,821 | 59.46 | — |
| Francis Perier | Option | 65,105 | 27.64 | — |
| Francis Perier | Option | 46,250 | 38.4 | — |
| Bhavesh Ashar | Option | 7,667 | 72.61 | — |
| Bhavesh Ashar | Option | 11,026 | 59.46 | — |
| Bhavesh Ashar | Option | 45,834 | 26.98 | — |
| Bhavesh Ashar | Option | 36,459 | 27.64 | — |
| Badreddin Edris | Option | 92,500 | 38.4 | — |
| Bhavesh Ashar | Option | 57,813 | 38.4 | — |
| Badreddin Edris | Option | 22,052 | 59.46 | — |
| Badreddin Edris | Option | 125,001 | 27.64 | — |
| James Cassidy | Option | 14,813 | 76.3 | — |
| James Cassidy | Option | 70,314 | 27.64 | — |
| James Cassidy | Option | 61,667 | 38.4 | — |
The Company's compensation policy is designed to attract and retain key executives and motivate management to enhance long-term stockholder value by striking a balance between responsible, measured compensation practices and effective incentives. The program primarily consists of base salary, short-term cash incentive compensation, and long-term incentive compensation in the form of equity awards, with a significant portion allocated to at-risk performance-based incentives.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-05-14 | 57,606,702 | 3,851,046 | 5,864,614 | 93.73% | Passed |
| 2024 | 2024-05-16 | 38,332,463 | 27,761,536 | 3,407,326 | 58% | Passed |
| 2023 | 2023-05-24 | 39,159,414 | 12,806,081 | 5,064,506 | 75.36% | Passed |
| 2022 | 2022-05-19 | 26,157,025 | 8,338,675 | 7,980,493 | 75.83% | Passed |
| 2021 | 2021-05-20 | 37,049,687 | 2,829,187 | 2,327,475 | 92.91% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-05-14 | 93.73%a |
| 2024 | 2024-05-16 | 58%b |
| 2023 | 2023-05-24 | 75.36%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 36 : 1 |
|---|---|
| CEO total compensation | $16,153,317 |
| Median employee compensation | $454,858 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Martin MackayIndependent · Not standing for re-election | $28,750 | $366,638 | $733,817 | $0 | $0 | $1,129,205 |
| Daniel S. LynchIndependent · Board Chair | 100,000 | 183,333 | 366,906 | 0 | 0 | 650,239 |
| Alan FuhrmanIndependent | 75,000 | 183,333 | 366,906 | 0 | 0 | 625,239 |
| Julie HambletonIndependent | 75,000 | 183,333 | 366,906 | 0 | 0 | 625,239 |
| Freda Lewis-HallIndependent · Not standing for re-election | 70,000 | 183,333 | 366,906 | 0 | 0 | 620,239 |
| Carlos AlbánIndependent · Not standing for re-election | 62,500 | 183,333 | 366,906 | 0 | 0 | 612,739 |
| Saqib IslamEmployee director · Not standing for re-election | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $550,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | $4 |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $411,250 |
| Equity awards (grant-date value) | $1,283,303 |
| All other compensation | $0 |
| Total cost of the board | $1,694,553 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies SpringWorks Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including SpringWorks Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TG Therapeutics, Inc. | 2025 | Michael Weiss | $875,000 | $23,550,000 | $0 | $1,146,250 | $25,571,250 |
| 2 | Immunovant, Inc. | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 3 | SpringWorks Therapeutics | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 4 | BridgeBio Pharma, Inc. | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 5 | Revolution Medicines, Inc. | 2025 | Mark Goldsmith | 812,500 | 3,968,076 | 8,995,114 | 889,700 | 14,672,390 |
| 6 | Blueprint Medicines Corp. | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 7 | Ultragenyx Pharmaceutical, Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 8 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 9 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 10 | ACADIA Pharmaceuticals, Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 11 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 12 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 13 | Deciphera Pharmaceuticals, Inc. | 2023 | Steven Hoerter | 738,200 | 1,935,000 | 2,837,100 | 487,212 | 6,010,712 |
| 14 | Agios Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 15 | Iovance Biotherapeutics, Inc. | 2025 | Frederick Vogt | 800,000 | 759,375 | 0 | 312,000 | 1,888,175 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| SpringWorks Therapeutics | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
| ACADIA Pharmaceuticals, Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Agios Pharmaceuticals, Inc. | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Blueprint Medicines Corp. | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| BridgeBio Pharma, Inc. | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Deciphera Pharmaceuticals, Inc. | 110% | Option 50 · PSU 50 · RSU 25 | No | Pearl Meyer & Partners, LLC |
| Immunovant, Inc. | 110% | not disclosed | No | Compensia |
| Iovance Biotherapeutics, Inc. | 60% | not disclosed | No | Haigh & Company |
| Revolution Medicines, Inc. | 146% | Options 70 · RSU 30 | not disclosed | Compensia |
| Sarepta Therapeutics, Inc. | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| TG Therapeutics, Inc. | 131% | RSU 100 | No | Compensia, Inc. |
| Ultragenyx Pharmaceutical, Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Saqib Islam | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Executive Compensation”. As printed: 16,153,317. Filing ↗machine: r1 · c47 · span 623184–623194 |
| 2 | Section 01, Badreddin Edris | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Executive Compensation”. As printed: 5,941,369. Filing ↗machine: r10 · c47 · span 666803–666812 |
| 3 | Section 01, James Cassidy | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Executive Compensation”. As printed: 4,088,074. Filing ↗machine: r13 · c47 · span 681001–681010 |
| 4 | Section 01, Bhavesh Ashar | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Executive Compensation”. As printed: 3,887,310. Filing ↗machine: r7 · c47 · span 651772–651781 |
| 5 | Section 01, Francis Perier | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Executive Compensation”. As printed: 3,226,124. Filing ↗machine: r4 · c47 · span 637902–637911 |
| 6 | Section 03, James Cassidy RSU | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r20 · c41 · span 803209–803218 |
| 7 | Section 03, Saqib Islam RSU | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 8 | Section 03, Bhavesh Ashar M.B.A. RSU | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r12 · c41 · span 763495–763504 |
| 9 | Section 03, Saqib Islam PSU | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 10 | Section 03, Francis I. Perier Jr. M.B.A. RSU | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r8 · c41 · span 743674–743681 |
| 11 | Section 03, Badreddin Edris RSU | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r16 · c41 · span 783335–783344 |
| 12 | Section 03, Bhavesh Ashar RSU | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 763495–763504 |
| 13 | Section 03, Francis Perier RSU | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 743674–743681 |
| 14 | Section 03, Bhavesh Ashar M.B.A. OPTION | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r13 · c44 · span 768583–768592 |
| 15 | Section 03, James Cassidy OPTION | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r21 · c44 · span 808313–808322 |
| 16 | Section 03, Badreddin Edris OPTION | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r17 · c44 · span 788440–788449 |
| 17 | Section 03, Francis I. Perier Jr. M.B.A. OPTION | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r9 · c44 · span 748760–748769 |
| 18 | Section 03, Saqib Islam OPTION | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 19 | Section 03, Bhavesh Ashar OPTION | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 768583–768592 |
| 20 | Section 03, Francis Perier OPTION | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 748760–748769 |
| 21 | Section 07, pay ratio | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “CEO Pay Ratio”. As printed: 36 : 1. Filing ↗ |
| 22 | Section 08, Martin Mackay | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Director Compensation”. As printed: 1,129,205. Filing ↗machine: span 330959–330968 |
| 23 | Section 08, Daniel S. Lynch | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Director Compensation”. As printed: 650,239. Filing ↗machine: span 315304–315311 |
| 24 | Section 08, Alan Fuhrman | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Director Compensation”. As printed: 625,239. Filing ↗machine: span 321534–321541 |
| 25 | Section 08, Julie Hambleton | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Director Compensation”. As printed: 625,239. Filing ↗machine: span 324637–324644 |
| 26 | Section 08, Freda Lewis-Hall | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Director Compensation”. As printed: 620,239. Filing ↗machine: span 318415–318422 |
| 27 | Section 08, Carlos Albán | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Director Compensation”. As printed: 612,739. Filing ↗machine: span 327761–327768 |
| 28 | Section 08, Saqib Islam | DEF 14A | 2025-04-04 | 0001104659-25-032187 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 29 | Section 02, Carlos Alban 2025-05-14 | Form 4 | 2025-05-15 | 0001104659-25-049656 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Freda Lewis-Hall 2025-05-14 | Form 4 | 2025-05-15 | 0001104659-25-049661 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Martin Mackay 2025-05-14 | Form 4 | 2025-05-15 | 0001104659-25-049655 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Alan Fuhrman 2025-05-14 | Form 4 | 2025-05-15 | 0001104659-25-049658 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Julie Hambleton 2025-05-14 | Form 4 | 2025-05-15 | 0001104659-25-049659 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Daniel S. Lynch 2025-05-14 | Form 4 | 2025-05-15 | 0001104659-25-049662 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Francis Perier 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065299 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Daniel S. Lynch 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065321 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Daniel S. Lynch 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065321 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Daniel S. Lynch 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065321 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Daniel S. Lynch 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065321 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Freda Lewis-Hall 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065318 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Daniel S. Lynch 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065321 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Daniel S. Lynch 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065321 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Badreddin Edris 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065322 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Badreddin Edris 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065322 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Badreddin Edris 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065322 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Herschel S. Weinstein 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065297 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Herschel S. Weinstein 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065297 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Herschel S. Weinstein 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065297 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Saqib Islam 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Daniel Pichl 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065300 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Daniel Pichl 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065300 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Daniel Pichl 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065300 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Daniel Pichl 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065300 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Michael Nofi 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065302 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Michael Nofi 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065302 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Michael Nofi 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065302 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Michael Nofi 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065302 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Michael Nofi 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065302 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Carlos Alban 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065303 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Carlos Alban 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065303 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, James Cassidy 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065305 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, James Cassidy 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065305 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Bhavesh Ashar 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065307 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Bhavesh Ashar 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065307 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Bhavesh Ashar 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065307 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Tai-An Lin 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065310 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Tai-An Lin 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065310 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Tai-An Lin 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065310 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Alan Fuhrman 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065312 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Alan Fuhrman 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065312 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Alan Fuhrman 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065312 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Freda Lewis-Hall 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065318 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Badreddin Edris 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065322 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Herschel S. Weinstein 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065297 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Saqib Islam 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Alan Fuhrman 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065312 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Freda Lewis-Hall 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065318 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Herschel S. Weinstein 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065297 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Herschel S. Weinstein 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065297 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Saqib Islam 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Saqib Islam 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Saqib Islam 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Francis Perier 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065299 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Francis Perier 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065299 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Francis Perier 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065299 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Martin Mackay 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065304 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, James Cassidy 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065305 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Bhavesh Ashar 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065307 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Bhavesh Ashar 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065307 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Tai-An Lin 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065310 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Tai-An Lin 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065310 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Francis Perier 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065299 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Badreddin Edris 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065322 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Badreddin Edris 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065322 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Carlos Alban 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065303 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Freda Lewis-Hall 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065318 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Freda Lewis-Hall 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065318 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Freda Lewis-Hall 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065318 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Martin Mackay 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065304 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Alan Fuhrman 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065312 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Alan Fuhrman 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065312 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Francis Perier 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065299 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Francis Perier 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065299 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, James Cassidy 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065305 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, James Cassidy 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065305 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Bhavesh Ashar 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065307 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Julie Hambleton 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065315 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Julie Hambleton 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065315 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Daniel S. Lynch 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065321 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Julie Hambleton 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065315 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Julie Hambleton 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065315 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Saqib Islam 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Saqib Islam 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Daniel S. Lynch 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065321 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Saqib Islam 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Badreddin Edris 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065322 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Badreddin Edris 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065322 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Saqib Islam 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Carlos Alban 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065303 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Michael Nofi 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065302 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Daniel Pichl 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065300 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Daniel Pichl 2025-07-01 | Form 4 | 2025-07-02 | 0001104659-25-065300 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 06, 2025 vote | Form 8-K | 2025-05-14 | 0001104659-25-048608 | Item 5.07 · say-on-pay result. As reported: 93.73% (votes for as printed: 57,606,702). Filing ↗ |
| 124 | Section 06, 2024 vote | Form 8-K | 2024-05-17 | 0001104659-24-063076 | Item 5.07 · say-on-pay result. As reported: 58% (votes for as printed: 38,332,463). Filing ↗ |
| 125 | Section 06, 2023 vote | Form 8-K | 2023-05-25 | 0001104659-23-064623 | Item 5.07 · say-on-pay result. As reported: 75.36% (votes for as printed: 39,159,414). Filing ↗ |
| 126 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 127 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 128 | Section 09b board cost (computed) | Computed | — | — | Cash 411,250 + equity 1,283,303 + all other 0 = 1,694,553, summed across the director compensation table rows.machine: formula: Σ = 1,694,553 |
| 129 | TG Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001437749-26-014233 | CEO total compensation as printed in TG Therapeutics, Inc.'s own proxy. As printed: 25,571,250. Filing ↗machine: r4 · c24 · span 404551–404561 |
| 130 | Immunovant, Inc., Section 10b CEO total | DEF 14A | 2026-07-22 | 0001764013-26-000092 | CEO total compensation as printed in Immunovant, Inc.'s own proxy. As printed: 20,158,767. Filing ↗machine: span 465716–465726 |
| 131 | SpringWorks Therapeutics (subject), Section 10b CEO total | DEF 14A | 2025-04-04 | 0001104659-25-032187 | CEO total compensation as printed in SpringWorks Therapeutics's own proxy. As printed: 16,153,317. Filing ↗machine: r1 · c47 · span 623184–623194 |
| 132 | BridgeBio Pharma, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016723 | CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531 |
| 133 | Revolution Medicines, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182453 | CEO total compensation as printed in Revolution Medicines, Inc.'s own proxy. As printed: 14,672,390. Filing ↗machine: r2 · c27 · span 382608–382618 |
| 134 | Blueprint Medicines Corp., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005415 | CEO total compensation as printed in Blueprint Medicines Corp.'s own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162 |
| 135 | Ultragenyx Pharmaceutical, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical, Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 136 | Apellis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 137 | Arcus Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001724521-26-000025 | CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749 |
| 138 | ACADIA Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals, Inc.'s own proxy. As printed: 8,256,518. Filing ↗ |
| 139 | Sarepta Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404 |
| 140 | Arvinas, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028156 | CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930 |
| 141 | Deciphera Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2024-04-25 | 0001654151-24-000012 | CEO total compensation as printed in Deciphera Pharmaceuticals, Inc.'s own proxy. As printed: 6,010,712. Filing ↗machine: span 605886–605895 |
| 142 | Agios Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177086 | CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194 |
| 143 | Iovance Biotherapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050458 | CEO total compensation as printed in Iovance Biotherapeutics, Inc.'s own proxy. As printed: 1,888,175. Filing ↗machine: r6 · c16 · span 797910–797919 |
| 144 | Section 10a, ACADIA Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include SpringWorks Therapeutics. Filing ↗ |
| 145 | Section 10a, Agios Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-177086 | Agios Pharmaceuticals, Inc. names SpringWorks Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 146 | Section 10a, Apellis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0000950170-25-056966 | Apellis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include SpringWorks Therapeutics. Filing ↗ |
| 147 | Section 10a, Revolution Medicines, Inc. reciprocity | DEF 14A | — | 0001193125-26-182453 | Revolution Medicines, Inc. names SpringWorks Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 148 | Section 10a, Sarepta Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include SpringWorks Therapeutics. Filing ↗ |
| 149 | Section 10a, Arvinas, Inc. reciprocity | DEF 14A | — | 0001628280-26-028156 | Arvinas, Inc. names SpringWorks Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 150 | Section 10a, TG Therapeutics, Inc. reciprocity | DEF 14A | — | 0001437749-26-014233 | TG Therapeutics, Inc. names SpringWorks Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 151 | Section 10a, Blueprint Medicines Corp. reciprocity | DEF 14A | — | 0001558370-25-005415 | Blueprint Medicines Corp.'s most recent proxy was read; its disclosed peer group does not include SpringWorks Therapeutics. Filing ↗ |
| 152 | Section 10a, Immunovant, Inc. reciprocity | DEF 14A | — | 0001764013-26-000092 | Immunovant, Inc. names SpringWorks Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 153 | Section 10a, Ultragenyx Pharmaceutical, Inc. reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical, Inc.'s most recent proxy was read; its disclosed peer group does not include SpringWorks Therapeutics. Filing ↗ |
| 154 | Section 10a, BridgeBio Pharma, Inc. reciprocity | DEF 14A | — | 0001140361-26-016723 | BridgeBio Pharma, Inc. names SpringWorks Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 155 | Section 10a, Iovance Biotherapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-050458 | Iovance Biotherapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include SpringWorks Therapeutics. Filing ↗ |
| 156 | Section 10a, Deciphera Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001654151-24-000012 | Deciphera Pharmaceuticals, Inc. names SpringWorks Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.